Yesterday, July 7, 2016, 36 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.65 to $319,584,654.18.

Highlighted Stocks Traded by Insiders:

Xplore Technologies (XPLR) - FREE Research Report

Leonardis Thomas, who is Director at Xplore Technologies, bought 2,000 shares at $2.42 on July 7, 2016. Following this transaction, the Director owned 36,876 shares meaning that the stake was boosted by 5.73% with the 2,000-share transaction.

The shares most recently traded at $2.39, down $0.03, or 1.25% since the insider transaction. Historical insider transactions for Xplore Technologies go as follows:

  • 4-Week # shares bought: 2,280
  • 12-Week # shares bought: 2,280
  • 24-Week # shares bought: 2,280

The average volume for Xplore Technologies has been 31,100 shares per day over the past 30 days. Xplore Technologies has a market cap of $26.7 million and is part of the technology sector and computer hardware industry. Shares are down 53.12% year-to-date as of the close of trading on Thursday.

Xplore Technologies Corp. develops, integrates, and markets rugged mobile personal computer systems (PCs) in the United States, Canada, and internationally. Currently, there is 1 analyst who rates Xplore Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XPLR - FREE

TheStreet Quant Ratings

rates Xplore Technologies as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and poor profit margins. Get the full

Xplore Technologies Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Aceto (ACET) - FREE Research Report

Guccione Salvatore J Sr, who is Chief Executive Officer at Aceto, sold 10,945 shares at $23.25 on July 7, 2016. Following this transaction, the Chief Executive Officer owned 144,042 shares meaning that the stake was reduced by 7.06% with the 10,945-share transaction.

Debenedittis Frank, who is Sr. Vice President at Aceto, sold 3,275 shares at $23.34 on July 7, 2016. Following this transaction, the Sr. Vice President owned 67,495 shares meaning that the stake was reduced by 4.63% with the 3,275-share transaction.

Roth Douglas A, who is Sr. Vice President & CFO at Aceto, sold 6,770 shares at $22.72 on July 7, 2016. Following this transaction, the Sr. Vice President & CFO owned 58,783 shares meaning that the stake was reduced by 10.33% with the 6,770-share transaction.

Eilender Albert L, who is Chairman at Aceto, sold 7,690 shares at $22.53 on July 7, 2016. Following this transaction, the Chairman owned 210,199 shares meaning that the stake was reduced by 3.53% with the 7,690-share transaction.

Bartone Raymond, who is Senior Vice President at Aceto, sold 2,392 shares at $22.41 on July 7, 2016. Following this transaction, the Senior Vice President owned 29,717 shares meaning that the stake was reduced by 7.45% with the 2,392-share transaction.

Shackley Nicolas I, who is Sr. Vice President at Aceto, sold 3,564 shares at $22.41 on July 7, 2016. Following this transaction, the Sr. Vice President owned 20,714 shares meaning that the stake was reduced by 14.68% with the 3,564-share transaction.

Rogers Steven, who is S.V.P. & Chief Legal Officer at Aceto, sold 3,275 shares at $22.50 on July 7, 2016. Following this transaction, the S.V.P. & Chief Legal Officer owned 11,943 shares meaning that the stake was reduced by 21.52% with the 3,275-share transaction.

Alaimo Charles John, who is Senior Vice President at Aceto, sold 3,639 shares at $22.41 on July 7, 2016. Following this transaction, the Senior Vice President owned 11,755 shares meaning that the stake was reduced by 23.64% with the 3,639-share transaction.

Srinivasan Satish, who is President & COO - Rising Pharm at Aceto, sold 3,250 shares at $22.80 on July 7, 2016. Following this transaction, the President & COO - Rising Pharm owned 16,116 shares meaning that the stake was reduced by 16.78% with the 3,250-share transaction.

Kippley Terry, who is Sr. Vice President at Aceto, sold 2,149 shares at $22.41 on July 7, 2016. Following this transaction, the Sr. Vice President owned 17,100 shares meaning that the stake was reduced by 11.16% with the 2,149-share transaction.

The shares most recently traded at $23.86, up $1.45, or 6.08% since the insider transaction. Historical insider transactions for Aceto go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 29,188
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 47,538

The average volume for Aceto has been 179,000 shares per day over the past 30 days. Aceto has a market cap of $684.0 million and is part of the health care sector and drugs industry. Shares are down 12.01% year-to-date as of the close of trading on Thursday.

Aceto Corporation, together with its subsidiaries, sources, markets, sells, and distributes pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products, and specialty chemicals. The stock currently has a dividend yield of 1.04%. The company has a P/E ratio of 17.1. Currently, there are 2 analysts who rate Aceto a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ACET - FREE

TheStreet Quant Ratings

rates Aceto as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Aceto Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Omnicell (OMCL) - FREE Research Report

Seim Robin Gene, who is EVP, Global A & M Adherence at Omnicell, sold 5,302 shares at $34.75 on July 7, 2016. Following this transaction, the EVP, Global A & M Adherence owned 50,118 shares meaning that the stake was reduced by 9.57% with the 5,302-share transaction.

The shares most recently traded at $35.10, up $0.35, or 1% since the insider transaction. Historical insider transactions for Omnicell go as follows:

  • 4-Week # shares sold: 7,933
  • 12-Week # shares sold: 8,700
  • 24-Week # shares sold: 56,385

The average volume for Omnicell has been 160,200 shares per day over the past 30 days. Omnicell has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are up 12.97% year-to-date as of the close of trading on Thursday.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. It operates through two segments, Automation and Analytics, and Medication Adherence. The company has a P/E ratio of 53.2. Currently, there are 5 analysts who rate Omnicell a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on OMCL - FREE

TheStreet Quant Ratings

rates Omnicell as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Omnicell Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.